Arcutis is financially strong, with over 30 months of cash runway. The atopic dermatitis market is large and shifting away ...

Rezpegaldesleukin, an investigational interleukin-pathway agonist, demonstrated efficacy and safety for people with moderate ...

According to long-term safety analyses of abrocitinib in moderate-to-severe atopic dermatitis, which of the following is a notable monitoring need?

In a meta-analysis of 42 studies, exposure to air pollutants and high temperatures was associated with higher risk for clinic ...

Rezpeg's promising Phase 2b data makes Nektar Therapeutics a strong contender in the AD market. Click here to read an ...

A focused update to AAD’s adult AD guidelines recommends tapinarof, roflumilast, lebrikizumab, and nemolizumab based on ...

New research published in Current Issues in Pharmacy and Medical Sciences found that a hemp seed oil-based topical emulsion ...

Finding an effective, safe medication to control itch is essential to maximize patient comfort. Because Zenrelia does not require a loading dose and is administered once daily, Zenrelia may help impro ...

[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...

Despite Nektar’s share price shooting up as much as 175% on Tuesday, William Blair maintained that “there is an absence of ...

Nektar Therapeutics NKTR announced that the phase IIb REZOLVE-AD study evaluating its lead pipeline candidate, ...

A new immune-modulating treatment has shown promising results for treating moderate to severe eczema, delivering fast itch ...